Concepedia

Publication | Closed Access

Multifunctional Smart Yolk–Shell Nanostructure with Mesoporous MnO<sub>2</sub> Shell for Enhanced Cancer Therapy

52

Citations

40

References

2020

Year

Abstract

Manganese dioxide (MnO<sub>2</sub>) nanostructures have aroused great interest among analytical and biological medicine researchers as a unique type of tumor microenvironment (TME)-responsive nanomaterial. However, reliable approaches for synthesizing yolk-shell nanostructures (YSNs) with mesoporous MnO<sub>2</sub> shell still remain exciting challenges. Herein, a YSN (size, ∼75 nm) containing a mesoporous MnO<sub>2</sub> shell and Er<sup>3+</sup>-doped upconversion/downconversion nanoparticle (UCNP) core with a large cavity is demonstrated for the first time. This nanostructure not only integrates diverse functional components including MnO<sub>2</sub>, UCNPs, and YSNs into one system but also endows a size-controllable hollow cavity and thickness-tunable MnO<sub>2</sub> layers, which can load various guest molecules like photosensitizers, methylene blue (MB), and the anticancer drugs doxorubicin (DOX). NIR-II fluorescence and photoacoustic (PA) imaging from UCNP and MB, respectively, can monitor the enrichment of the nanomaterials in the tumors for guiding chemo-photodynamic therapy (PDT) <i>in vivo</i>. In the TME, degradation of the mMnO<sub>2</sub> shell by H<sub>2</sub>O<sub>2</sub> and GSH not only generates Mn<sup>2+</sup> for tumor-specific T<sub>1</sub>-MR imaging but also releases O<sub>2</sub> and drugs for tumor-specific treatment. The result confirmed that imaging-guided enhanced chemo-PDT combination therapy that benefited from the unique structural features of YSNs could substantially improve the therapeutic effectiveness toward malignant tumors compared to monotherapy.

References

YearCitations

Page 1